(Q46527001)

22 December 2017

review article

1 reference

title

Next generation antibody drugs: pursuit of the 'high-hanging fruit'. (English)

1 reference

22 December 2017

author name string

Paul J Carter

series ordinal

1

1 reference

22 December 2017

Greg A Lazar

series ordinal

2

1 reference

22 December 2017

publication date

1 December 2017

1 reference

22 December 2017

Nature Reviews Drug Discovery

published in

1 reference

22 December 2017

https://scigraph.springernature.com/pub.10.1038/nrd.2017.227

exact match

0 references

cites work

Development trends for human monoclonal antibody therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Antibodies to watch in 2017

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Editorial overview: Special section: New concepts in antibody therapeutics: What's in store for antibody therapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Monoclonal antibody biosimilars

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Cost-Effectiveness and Clinical Practice Guidelines: Have We Reached a Tipping Point?-An Overview

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Immunocytokines for cancer treatment: past, present and future

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Therapeutic T cell engineering

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Therapeutic antibodies for autoimmunity and inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Coming-of-Age of Antibodies in Cancer Therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Mechanisms of action of therapeutic antibodies for cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Antibody Drug Conjugates for Cancer Therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Antibody drug conjugates: lessons from 20 years of clinical experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Strategies and challenges for the next generation of antibody-drug conjugates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Hybrid antibodies can target sites for attack by T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

A review of blinatumomab, a novel immunotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

The making of bispecific antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

The use of CrossMAb technology for the generation of bi- and multispecific antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Alternative molecular formats and therapeutic applications for bispecific antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Biophysical properties of the clinical-stage antibody landscape.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Engineering of stable bispecific antibodies targeting IL-17A and IL-23.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

A modeling analysis of the effects of molecular size and binding affinity on tumor targeting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Targeting T cells to tumor cells using bispecific antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

ImmTACs for targeted cancer therapy: Why, what, how, and which

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Opportunities and challenges for TCR mimic antibodies in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Selective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Humanization of an anti-p185HER2 antibody for human cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Trastuzumab emtansine for HER2-positive advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Orthogonal Cysteine Protection Enables Homogeneous Multi-Drug Antibody-Drug Conjugates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Efficient Payload Delivery by a Bispecific Antibody-Drug Conjugate Targeting HER2 and CD63.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Improved Lysosomal Trafficking Can Modulate the Potency of Antibody Drug Conjugates.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Novel antibody-antibiotic conjugate eliminates intracellular S. aureus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

An immunosuppressive antibody-drug conjugate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Modulation of antibody effector function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Marketing approval of mogamulizumab: a triumph for glyco-engineering

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Structural analysis of Fc/FcγR complexes: a blueprint for antibody design.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Engineered antibody Fc variant with selectively enhanced Fc RIIb binding over both Fc RIIaR131 and Fc RIIaH131

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Structural Basis for Enhanced HIV-1 Neutralization by a Dimeric Immunoglobulin G Form of the Glycan-Recognizing Antibody 2G12

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Complement is activated by IgG hexamers assembled at the cell surface

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Insights into the molecular basis of a bispecific antibody's target selectivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Improving target cell specificity using a novel monovalent bispecific IgG design

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

The blockade of immune checkpoints in cancer immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Enhancement of antitumor immunity by CTLA-4 blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

The future of immune checkpoint therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Industry 'road tests' new wave of immune checkpoints

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Elements of cancer immunity and the cancer-immune set point

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Antibody mimicry, receptors and clinical applications.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Monoclonal antibodies to purified muscarinic receptor display agonist-like activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Biopharmaceutical benchmarks 2014

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Thrombocytopenia caused by the development of antibodies to thrombopoietin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Activation of the erythropoietin (EPO) receptor by bivalent anti-EPO receptor antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

A potent erythropoietin-mimicking human antibody interacts through a novel binding site

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Switching constant domains enhances agonist activities of antibodies to a thrombopoietin receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Antibody-mediated activation of FGFR1 induces FGF23 production and hypophosphatemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Non-antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Factor VIII inhibitors in hemophilia A: rationale and latest evidence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fcγ receptor IIb inhibitory receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcγRIIb and CD19.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Principles of antibody-mediated TNF receptor activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Epitopes and functional responses defined by a panel of anti-Fas (CD95) monoclonal antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Rationale for anti-OX40 cancer immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Pharmacological modulation of GITRL/GITR system: therapeutic perspectives.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Agonistic CD40 antibodies and cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

4-1BB agonism: adding the accelerator to cancer immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Fcgamma receptors as regulators of immune responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Clinical pharmacokinetics of therapeutic monoclonal antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Prediction of the normal blood volume. Relation of blood volume to body habitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Pharmacokinetic aspects of retinal drug delivery.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

CSF, blood-brain barrier, and brain drug delivery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Development of high concentration protein biopharmaceuticals: the use of platform approaches in formulation development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Developability studies before initiation of process development: improving manufacturability of monoclonal antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Developability assessment during the selection of novel therapeutic antibodies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Aggregation risk prediction for antibodies and its application to biotherapeutic development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Distinct aggregation mechanisms of monoclonal antibody under thermal and freeze-thaw stresses revealed by hydrogen exchange

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Resolving self-association of a therapeutic antibody by formulation optimization and molecular approaches

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Viscosity of high concentration protein formulations of monoclonal antibodies of the IgG1 and IgG4 subclass - prediction of viscosity through protein-protein interaction measurements.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Highly viscous antibody solutions are a consequence of network formation caused by domain-domain electrostatic complementarities: insights from coarse-grained simulations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

A novel screening method to assess developability of antibody-like molecules

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Discovery of highly soluble antibodies prior to purification using affinity-capture self-interaction nanoparticle spectroscopy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Effect of Target Dynamics on Pharmacokinetics of a Novel Therapeutic Antibody against the Epidermal Growth Factor Receptor: Implications for the Mechanisms of Action

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Complex pharmacokinetics of a humanized antibody against human amyloid beta peptide, anti-abeta Ab2, in nonclinical species.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Effects of charge on antibody tissue distribution and pharmacokinetics.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

A strategy for risk mitigation of antibodies with fast clearance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Chaperone proteins as single component reagents to assess antibody nonspecificity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Reduced elimination of IgG antibodies by engineering the variable region.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

pH-dependent antigen-binding antibodies as a novel therapeutic modality.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Targeting FcRn for the modulation of antibody dynamics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

An engineered human IgG1 antibody with longer serum half-life.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Enhanced antibody half-life improves in vivo activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Target-independent variable region mediated effects on antibody clearance can be FcRn independent

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Assessing the Immunogenicity of Biopharmaceuticals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Antidrug Antibodies in Patients Treated with Alirocumab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Immunogenicity of engineered antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Immunogenicity assessment during the development of protein therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Delivering safer immunotherapies for cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

19. Targeted nanoparticles for smarter cancer therapy: Original research article: Folate receptor targeted biodegradable polymeric doxorubicin micelles, 2004

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Ten years of anti-vascular endothelial growth factor therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Ranibizumab for neovascular age-related macular degeneration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

VEGF-Trap: a VEGF blocker with potent antitumor effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Antibody therapies and their challenges in the treatment of age-related macular degeneration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Population Pharmacokinetics and Pharmacodynamics of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Risks of intravitreous injection: a comprehensive review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Contribution of Antibody Hydrodynamic Size to Vitreal Clearance Revealed through Rabbit Studies Using a Species-Matched Fab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Long-acting protein drugs for the treatment of ocular diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Design and Pharmacokinetic Characterization of Novel Antibody Formats for Ocular Therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Inhaled proteins: challenges and perspectives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Inhaled protein/peptide-based therapies for respiratory disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Dornase alfa (Pulmozyme).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Inhaled Insulin: A Clinical and Historical Review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Nebulized anti-IL-13 monoclonal antibody Fab' fragment reduces allergen-induced asthma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

The airways, a novel route for delivering monoclonal antibodies to treat lung tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

PEGylation prolongs the pulmonary retention of an anti-IL-17A Fab' antibody fragment after pulmonary delivery in three different species

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Nanobodies® as inhaled biotherapeutics for lung diseases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Survival and digestibility of orally-administered immunoglobulin preparations containing IgG through the gastrointestinal tract in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Oral delivery of macromolecular drugs: Where we are after almost 100years of attempts.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

AVX-470: a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

FcRn binding is not sufficient for achieving systemic therapeutic levels of immunoglobulin G after oral delivery of enteric-coated capsules in cynomolgus macaques

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

The global prevalence of dementia: a systematic review and metaanalysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Failed Alzheimer's trial does not kill leading theory of disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

The amyloid hypothesis of Alzheimer's disease at 25 years

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Stop Alzheimer's before it starts.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Antibody therapies in CNS diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain barrier penetrating bi-specific antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

A draft map of the human proteome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

A comprehensive map of molecular drug targets.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Evolutionary survey of druggable protein targets with respect to their subcellular localizations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Screening-based approaches to identify small molecules that inhibit protein-protein interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

In vitro and ex vivo strategies for intracellular delivery.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Delivery of antibody mimics into mammalian cells via anthrax toxin protective antigen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Efficient cell-specific uptake of binding proteins into the cytoplasm through engineered modular transport systems

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

A quantitative comparison of cytosolic delivery via different protein uptake systems.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

A general strategy for generating intact, full-length IgG antibodies that penetrate into the cytosol of living cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

A "Trojan horse" bispecific-antibody strategy for broad protection against ebolaviruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Safety and pharmacokinetics of XOMA 3AB, a novel mixture of three monoclonal antibodies against botulinum toxin A.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Oligoclonal antibodies to target the ErbB family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Single-batch production of recombinant human polyclonal antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Non-viral adeno-associated virus-based platform for stable expression of antibody combination therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Opportunities for therapeutic antibodies directed at G-protein-coupled receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Discovery of functional antibodies targeting ion channels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.227

7 January 2021

inferred from DOI database lookup

Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo

1 reference

12 December 2020

Measurement of IgG and albumin content of cerebrospinal fluid, and its interpretation

1 reference

12 December 2020

Homodimerization of erythropoietin receptor by a bivalent monoclonal antibody triggers cell proliferation and differentiation of erythroid precursors.

1 reference

12 December 2020

An agonist murine monoclonal antibody to the human c-Mpl receptor stimulates megakaryocytopoiesis

1 reference

12 December 2020

Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases

1 reference

12 December 2020

The potency of erythropoietin-mimic antibodies correlates inversely with affinity

1 reference

12 December 2020

Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target

1 reference

12 December 2020

The blood-retina barrier: tight junctions and barrier modulation.

1 reference

12 December 2020

Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy

1 reference

12 December 2020

A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells

1 reference

12 December 2020

Ocular delivery of macromolecules

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD.2017.227

1 reference

22 December 2017

1 reference

22 December 2017